The short version of Anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
=== Pharmacokinetics === After application to the skin, miconazole can be measured in the skin for up to four days, but less than 1% is absorbed into the bloodstream. When applied to the oral mucosa (and possibly also for vaginal use), it is significantly absorbed. In the bloodstream, 88.2% are bound to plasma proteins and 10.6% to blood cells. The substance is partly metabolized via the liver enzyme CYP3A4 and mainly eliminated via the faeces.
Many new features for tandem mass analysis were gradually revealed by using the digital ion trap. Ions can be selectively removed from the ion trap by boundary ejection simply by varying the duty cycle of the digital waveform, instead of applying the conventional "resolving DC" voltage. Since rectangular waveforms are employed in the DIT, electrons can be injected into the trap during one of the voltage level without being accelerated up by the varying electric field. This enabled Electron-capture dissociation, which needs very low energy electron beam to interact with the trapped ions, achieved in the digital ion trap, without assistance of a magnetic field. Other forms of digital ion trap were also developed, including the linear ion trap constructed using printed circuit boards and the rods structure linear ion guide/trap. Two sets of switch circuitry were normally used to generate 2 phases of rectangular pulse waveform for two pairs of rods in case of the linear digital ion trap.
Edge noted in 2003 that "a significant number of the 7.5m copies of the PC version were bought because the game offered such potential for community-driven expansion". As of November 16, 2004, eight million copies had been sold, and by 2008, 9.3 million copies had been sold at retail. Guinness World Records awarded Half-Life the world record for Best-Selling First-Person Shooter of All Time (PC) in 2008.
In 1987, Yates purchased Temple Gym on Temple Street in Birmingham. In 2006, he franchised four additional Temple Gym locations, three of which are in the UK. As of 2020, only the original Birmingham gym is still in operation; it later relocated from Temple Street to the city's Jewellery Quarter. In 1994, Yates and bodybuilding brothers Mike and Ray Mentzer formed the California-based company Heavy Duty Inc., which marketed athletic apparel and bodybuilding books. In 1998, he partnered with Kerry Kayes to form the bodybuilding supplement company CNP Professional, which marketed a "Dorian Yates Approved" product line in the U.S. He left the company in 2006 to form his own company, Dorian Yates Ultimate Formulas, which offers a line of protein and weight-gain supplements. Yates started a second company in 2010 called EU Peptides, which sells peptide hormones and other pro-hormone supplements. He left this company in 2012, having founded a third company called DY Nutrition in 2011; it specializes in pre-workout formulas, has released several training DVDs, and offers a line of workout related supplements endorsed by Yates.
== Race swap controversy == Psylocke was initially the code name of Elizabeth Braddock, a British woman. However, in a Marvel storyline of 1989, Acts of Vengeance, she was "physically transformed into an Asian woman by a villain seeking to brainwash her and turn her into an elite assassin for a group of ninja warriors." This has been criticized as racially insensitive or stereotypical by multiple fans and critics. For example, Anna Lam calls her new form a "fetishized Asian sex object in the style of the classic Dragon Lady of the 1930s." Chris Claremont, the writer of the story, has said that this transformation was originally simply a disguise but became semi-permanent because most fans embraced it. The artist for the story is Jim Lee, a Korean American. The subsequent storyline of 1993, written by Nicieza, mitigates the issue because subsequently the East Asian Psylocke and the white Psylocke are two distinct women (Kwannon and Betsy Braddock, respectively).
Sources: en.wikipedia.org
=== Potential risks === As BLCO contains materials like vanadium, nickel and PAH, those tend to be harmful and disturb possibility of antioxidant. Heavy metals are necessary in metabolic process of creatures; however, they are the causes of physiological stress at the same time. Pollution problems by oil spills like soils contamination are continuous and prevalent, putting severe health and environmental threats. The pollutants can gradually accumulate in food chains and interrupt biological actions of creatures. Petroleum contaminants are pernicious to nature and moreover, their hydrocarbon elements which are mutagenic and causing cancers, entail immunomodulatory impacts on humans and organisms as well. The symptoms of risks can appear immediately or emerge after some time.
From 13 to 15 May 2026, the president of the United States Donald Trump made a state visit to China. This visit was Trump's second state visit to China, and the first to occur during his second presidency. Trump's first state visit to China occurred in November 2017. This trip was also the first by a U.S. president since Trump's visit in 2017. During the visit, Trump was received by CCP general secretary Xi Jinping at the Great Hall of the People, where the two leaders held talks. Xi announced the two sides had agreed to establish a Constructive Strategic and Stable Relationship. Following the talks, Xi and Trump visited the Temple of Heaven, the second US president to visit the Temple while in office after President Gerald Ford in 1975. Later, Xi hosted Trump for a dinner banquet at the Golden Room of the Great Hall of the People. Trump invited Xi for a state visit to the United States on 24 September 2026. At the second day of the visit on 15 May, Trump visited the Chinese leadership compound Zhongnanhai. The visit was the first of the four summits between Xi and Trump in 2026. It was reciprocated by a state visit by Xi Jinping to the United States in September 2026. Additionally, Trump is scheduled travel to China for APEC 2026 in November while Xi is scheduled to visit the United States for 2026 G20 Miami summit in December.
== Selecting discriminatory peptides == Finally, sophisticated normalization methods are used to remove systematic artefacts in the peptide intensity values between LC-MS measurements. Then, discriminatory peptides are identified by selecting the peptides whose normalized intensities are different (e.g., p-value < 0.05) among multiple groups of samples. In addition, newer hybrid mass spectrometers like LTQ OrbiTrap offer the possibility to acquire MS/MS peptide identifications in parallel to the high mass precision measurement of peptides on the MS1 level. This raises the computational challenge for the processing and integration of these two sources of information and has led to the development of novel promising quantification strategies.
Drugs may be modified to be slowly activated by the body, or be absorbed slowly by the body. Many are dissolved in an organic oil, as the compound is lipophilic due to the addition of functional groups to provide slow action. An example of this is adding a functional group such as decanoate. The combination of an oil base and modification to decrease metabolic activation prevent medications from being fully released. This can result in length of activity of 2–4 weeks or more. The alteration of the pharmacokinetics of the drug (the absorption and activation) does not change the side effect profile of the medication; thus, atypical antipsychotics are still preferred over typical antipsychotics.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.